ImmuCell Corp. Announces Annual Meeting of Stockholders on June 13, 2024
Ticker: ICCC · Form: DEF 14A · Filed: Apr 26, 2024 · CIK: 811641
| Field | Detail |
|---|---|
| Company | Immucell Corp /De/ (ICCC) |
| Form Type | DEF 14A |
| Filed Date | Apr 26, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: Annual Meeting, Proxy Statement, Director Election, Executive Compensation, Auditor Ratification
TL;DR
<b>ImmuCell Corporation will hold its Annual Meeting of Stockholders on June 13, 2024, to vote on director elections, executive compensation, and auditor ratification.</b>
AI Summary
IMMUCELL CORP /DE/ (ICCC) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Annual Meeting of Stockholders to be held remotely via live audio webcast and telephone conference call on June 13, 2024, at 9:30 AM ET. Key proposals include the election of directors, an advisory vote to approve executive compensation, and ratification of Wipfli LLP as the independent registered public accounting firm for fiscal year 2024. The record date for determining stockholders entitled to notice and voting is April 15, 2024. The company is incorporated in Delaware and its fiscal year ends on December 31. The filing is a Definitive Proxy Statement (DEF 14A) filed on April 26, 2024.
Why It Matters
For investors and stakeholders tracking IMMUCELL CORP /DE/, this filing contains several important signals. Stockholders will have the opportunity to vote on the composition of the Board of Directors and the company's executive compensation practices. The ratification of Wipfli LLP as the independent auditor is crucial for financial transparency and regulatory compliance.
Risk Assessment
Risk Level: low — IMMUCELL CORP /DE/ shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information that would alter the company's risk profile.
Analyst Insight
Stockholders should review the proposals regarding director elections and executive compensation before the June 13, 2024 meeting.
Key Numbers
- June 13, 2024 — Annual Meeting Date (Date of the Annual Meeting of Stockholders)
- 9:30 AM ET — Meeting Time (Time of the Annual Meeting of Stockholders)
- April 15, 2024 — Record Date (Record date for determining stockholders entitled to notice and voting)
- 2024 — Fiscal Year (Fiscal year for which Wipfli LLP is proposed as auditor)
Key Players & Entities
- IMMUCELL CORP /DE/ (company) — Registrant
- Wipfli LLP (company) — Independent Registered Public Accounting Firm
- June 13, 2024 (date) — Annual Meeting date
- April 15, 2024 (date) — Record date
- 2024 (date) — Fiscal year
- DE (jurisdiction) — State of Incorporation
- 1231 (date) — Fiscal Year End
- DEF 14A (form_type) — Filing type
FAQ
When did IMMUCELL CORP /DE/ file this DEF 14A?
IMMUCELL CORP /DE/ filed this Proxy Statement (DEF 14A) with the SEC on April 26, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by IMMUCELL CORP /DE/ (ICCC).
Where can I read the original DEF 14A filing from IMMUCELL CORP /DE/?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by IMMUCELL CORP /DE/.
What are the key takeaways from IMMUCELL CORP /DE/'s DEF 14A?
IMMUCELL CORP /DE/ filed this DEF 14A on April 26, 2024. Key takeaways: Annual Meeting of Stockholders to be held remotely via live audio webcast and telephone conference call on June 13, 2024, at 9:30 AM ET.. Key proposals include the election of directors, an advisory vote to approve executive compensation, and ratification of Wipfli LLP as the independent registered public accounting firm for fiscal year 2024.. The record date for determining stockholders entitled to notice and voting is April 15, 2024..
Is IMMUCELL CORP /DE/ a risky investment based on this filing?
Based on this DEF 14A, IMMUCELL CORP /DE/ presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information that would alter the company's risk profile.
What should investors do after reading IMMUCELL CORP /DE/'s DEF 14A?
Stockholders should review the proposals regarding director elections and executive compensation before the June 13, 2024 meeting. The overall sentiment from this filing is neutral.
How does IMMUCELL CORP /DE/ compare to its industry peers?
ImmuCell Corporation operates in the life sciences sector, specifically focusing on in vitro & in vivo diagnostic substances.
Are there regulatory concerns for IMMUCELL CORP /DE/?
The filing is made under Section 14(a) of the Securities Exchange Act of 1934, governing proxy solicitations.
Industry Context
ImmuCell Corporation operates in the life sciences sector, specifically focusing on in vitro & in vivo diagnostic substances.
Regulatory Implications
The filing is made under Section 14(a) of the Securities Exchange Act of 1934, governing proxy solicitations.
What Investors Should Do
- Review the proxy materials for detailed information on director nominees and executive compensation.
- Vote on the election of directors and the advisory resolution on executive compensation.
- Consider the ratification of Wipfli LLP as the independent registered public accounting firm for fiscal year 2024.
Key Dates
- 2024-06-13: Annual Meeting of Stockholders — To elect directors, vote on executive compensation, and ratify auditor appointment.
- 2024-04-15: Record Date — Determines stockholders eligible to vote at the Annual Meeting.
- 2024-04-26: Filing Date — Date the Definitive Proxy Statement was filed with the SEC.
Year-Over-Year Comparison
This filing is a DEF 14A (Definitive Proxy Statement) for the upcoming annual meeting, providing details on proposals and meeting logistics, rather than a report on financial performance.
Filing Stats: 4,391 words · 18 min read · ~15 pages · Grade level 14.5 · Accepted 2024-04-26 09:00:02
Filing Documents
- ea0204173-01.htm (DEF 14A) — 767KB
- tbarchart_001.jpg (GRAPHIC) — 298KB
- tbarchart_002.jpg (GRAPHIC) — 274KB
- 0001213900-24-036378.txt ( ) — 1557KB
From the Filing
DEF 14A 1 ea0204173-01.htm PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ SCHEDULE 14A ________________ Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.     ) Filed by the Registrant   Filed by a Party other than the Registrant   Check the appropriate box:   Preliminary Proxy Statement   Confidential, for Use of the Commission Only (as permitted by Rule 14a -6 (e)(2)   Definitive Proxy Statement   Definitive Additional Materials   Soliciting Material Pursuant to Section 240.14a -12 IMMUCELL CORPORATION (Name of Registrant as Specified In Its Charter) _________________________________________________________________ (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply):   No fee required   Fee paid previously with preliminary materials   Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a -6 (i)(1) and 0 -11   ImmuCell Corporation Notice of Annual Meeting of Stockholders June 13, 2024 To the Stockholders of ImmuCell Corporation: NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders of ImmuCell Corporation (the Company) will be held remotely via a live audio webcast as well as a telephone conference call on Thursday, June 13, 2024 at 9:30 AM ET for the following purposes: 1.        Election of Directors:     To elect a Board of Directors to serve until the next Annual Meeting of Stockholders and until their successors are qualified and elected (Proposal One); 2.        Advisory Vote to Approve Executive Compensation:     To consider a non -binding advisory resolution on the Company’s executive compensation program (Proposal Two); 3.        Ratification of the Appointment of the Independent Registered Public Accounting Firm:     To ratify the selection by the Audit Committee of the Board of Directors of Wipfli LLP as the Independent Registered Public Accounting Firm for the Company for the year ending December 31, 2024 (Proposal Three); and 4.        Other Business:     To conduct such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof, including approving any such adjournment or postponement, if necessary. The Board of Directors has fixed the close of business on Monday, April 15, 2024 as the record date for the determination of stockholders entitled to notice of, and to vote at, the Annual Meeting.   By Order of the Board of Directors     /s/ Michael F. Brigham     Michael F. Brigham, Secretary     April 26, 2024 The Annual Meeting will be conducted remotely via a live audio webcast as well as a telephone conference call at the date and time listed above. Details on how stockholders can participate in the Annual Meeting will be available at www.immucell.com , including information on how stockholders entitled to vote at the Annual Meeting can vote their shares if they elect not to do so in advance of the Annual Meeting. If you do expect to vote at the Annual Meeting, please contact our Voting Inspector in advance of the meeting at (207) 878 -2770 Ext. 0 or via email at mail@immucell.com. WHETHER OR NOT YOU EXPECT TO ATTEND THE ANNUAL MEETING IN PERSON (THROUGH THE LIVE AUDIO WEBCAST OR THE TELEPHONE CONFERENCE CALL), PLEASE COMPLETE, DATE AND SIGN THE ACCOMPANYING PROXY CARD AND RETURN IT PROMPTLY IN THE ENVELOPE ENCLOSED FOR THAT PURPOSE. THE GIVING OF SUCH PROXY WILL NOT AFFECT YOUR RIGHT TO VOTE IF YOU ATTEND THE MEETING IN PERSON (THROUGH THE LIVE AUDIO WEBCAST OR VIA THE TELEPHONE CONFERENCE CALL).   ImmuCell Corporation 56 Evergreen Drive Portland, ME 04103 PROXY STATEMENT Annual Meeting of Stockholders to be Held on June 13, 2024 This Proxy Statement is furnished in connection with the solicitation by the Board of Directors of ImmuCell Corporation (the Company), a Delaware corporation, of proxies to be voted at the Annual Meeting of Stockholders of the Company to be held at 9:30 AM ET on Thursday, June 13, 2024 remotely via a live audio webcast and telephone conference call, and any and all adjournments thereof,